Loading...
01/10 00:34
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals a strong financial performance with record medical cannabis revenue and improved margins. Despite lower consumer cannabis revenue, strategic focus on high-margin medical cannabis and international growth are promising. Positive cash flow and no cannabis business debt highlight financial health. The Q&A section reveals challenges in Europe but also demonstrates management's proactive strategies. While SG&A expenses are higher, they are partly one-time. Overall, the optimistic guidance for future EBITDA and market expansion suggests a positive sentiment, likely resulting in a stock price increase in the short term.
Net Revenue $98 million, a 17% increase year-over-year, driven by 37% growth in global medical cannabis revenue and 85% growth in international revenue.
Adjusted Gross Margin 52%, an improvement of 1,000 basis points year-over-year, attributed to higher cannabis margins and favorable portfolio mix.
Adjusted EBITDA $10.8 million, a 209% increase from $3.5 million in the year-ago period, driven by higher net revenue and gross profit.
Free Cash Flow $9.2 million, a 42% increase from $6.5 million in the year-ago period, due to higher net revenue, improved contribution margin, favorable working capital changes, and lower capital expenditures.
Cash and Cash Equivalents $186 million, with no cannabis business debt, highlighting a strong balance sheet.
Medical Cannabis Net Revenue $64.8 million, a 37% increase year-over-year, driven by 85% growth in international markets and strong contributions from Canadian medical cannabis.
Medical Cannabis Adjusted Gross Margin 69%, up from 67% year-over-year, due to higher revenue from international markets, cost reductions, and improved production efficiency.
Consumer Cannabis Net Revenue $7.9 million, down from $11.5 million year-over-year, reflecting a strategic focus on higher-margin medical cannabis.
Consumer Cannabis Adjusted Gross Margin 33%, up from 20% year-over-year, due to sales of higher-margin products and cost improvements.
Plant Propagation Net Revenue $23.9 million, a 4% increase year-over-year, attributed to organic growth and expanded product offerings.
Plant Propagation Adjusted Gross Margin 6%, down from 18% year-over-year, due to nonrecurring inventory write-offs and surplus crops not sold.
Adjusted SG&A $37.4 million, a 19% increase year-over-year, driven by higher selling and distribution costs and costs from the acquisition of MedReleaf Australia.
New proprietary cultivars in Poland: Launched two new proprietary cultivars, marking the highest potency medical cannabis products in the country. These products are grown and manufactured in GMP-certified Canadian facilities.
Proprietary cultivar-specific inhalable cannabis extracts in the U.K.: Successfully launched a new product category, expanding the variety of high-quality medical cannabis available in the U.K.
International revenue growth: International revenue grew 85%, driven by strong performance in markets like Germany, Poland, and the U.K.
Market expansion in Australia and New Zealand: Australia is the second-largest market for Aurora, holding the #2 market share. New Zealand is identified as an emerging and growing market with high barriers to entry.
European market developments: Germany's descheduling in 2024 has led to increased patient registrations and higher prescription volumes. New markets like Switzerland and Austria are online, with positive developments in France, Turkey, and Ukraine.
Operational efficiencies: Lower production costs achieved through yield improvement, new cultivation technology, and strong third-party partnerships.
Adjusted gross margin improvement: Adjusted gross margin improved by 1,000 basis points to 52%, driven by higher cannabis margins and favorable portfolio mix.
Focus on high-margin medical cannabis: Medical cannabis now comprises 66% of net revenue, up from 57% in the previous year, with a focus on international markets.
Debt-free cannabis business: Aurora's cannabis business is completely debt-free, with $186 million in cash and no need for dilutive capital raises.
Regulatory Changes in Germany: Potential regulatory changes in Germany could impact the company's growth plans, although no immediate significant rollback is expected.
Competitive Pressures in Australia: The Australian market is highly regulated and attracting new entrants, which could increase competition despite Aurora's strong positioning.
Temporary Headwinds in Poland: Regulatory changes in Poland previously impacted prescription volumes, though these headwinds have been resolved.
Nonrecurring Quality Issues in Plant Propagation: Inventory write-offs due to a nonrecurring quality issue and surplus crops not sold impacted margins in the plant propagation segment.
Incremental Costs from MedReleaf Australia Acquisition: Higher selling and distribution costs were incurred due to the acquisition of MedReleaf Australia, impacting SG&A expenses.
Q2 2026 Revenue Growth: Consolidated net revenue is expected to increase year-over-year, driven primarily by 8% to 12% growth in the Global Medical Cannabis segment.
Plant Propagation Revenue: Expected to perform in line with traditional seasonal trends, with 25% to 35% of revenues normally earned in the second half of the calendar year.
Adjusted Gross Margins: Consolidated adjusted gross margins are expected to increase, driven primarily by 250 to 475 basis points growth in the cannabis business, with plant propagation adjusted gross margins expected to mostly perform in line with historical trends.
Adjusted EBITDA: Improvements in adjusted gross margins and higher global medical cannabis revenue should lead to continued strong positive adjusted EBITDA.
Free Cash Flow: While free cash flow is expected to be positive on an annual basis for the second consecutive year, there will be several significant cash outflows in line with historical trends that will impact free cash flow results in Q2 2026.
The selected topic was not discussed during the call.
The earnings call presents a mixed bag: strong growth in medical cannabis and plant propagation segments, but declining consumer cannabis revenue and increased SG&A expenses. The Q&A highlights structural advantages in international markets but reveals uncertainties in regulatory environments and cash flow challenges. Despite positive adjusted net income and margin improvements, negative free cash flow and unclear guidance on regulatory impacts temper optimism. Without market cap details, a neutral stance is prudent, reflecting balanced positive and negative factors.
The earnings call reveals a strong financial performance with record medical cannabis revenue and improved margins. Despite lower consumer cannabis revenue, strategic focus on high-margin medical cannabis and international growth are promising. Positive cash flow and no cannabis business debt highlight financial health. The Q&A section reveals challenges in Europe but also demonstrates management's proactive strategies. While SG&A expenses are higher, they are partly one-time. Overall, the optimistic guidance for future EBITDA and market expansion suggests a positive sentiment, likely resulting in a stock price increase in the short term.
The earnings call highlighted strong financial performance with a 34% revenue growth and a significant increase in adjusted EBITDA. Despite a temporary decline in Poland, management provided optimistic guidance, particularly with international market expansion plans. The Q&A revealed confidence in overcoming competitive challenges and maintaining supply levels. Although management was vague on some specifics, the overall sentiment remained positive, especially with strong margins and no debt. Given these factors, a positive stock price movement is anticipated over the next two weeks.
Aurora Cannabis has shown strong financial performance with a 37% increase in net revenue, positive free cash flow, and no cannabis business debt. The company is expanding internationally, particularly in favorable regulatory environments like Europe and Australia, and maintains high margins. While there are supply chain and competitive pressures, Aurora's strategic focus on operational excellence and profitability is reassuring. The Q&A session revealed confidence in managing supply challenges and sustaining margins, contributing to a positive outlook. Despite some uncertainties in competition and data, the overall sentiment is positive, suggesting a likely stock price increase.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
